The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Darapladib for Preventing Ischemic Events in Stable Coronary Heart Disease
Open accessAbstract
BACKGROUND: Elevated lipoprotein-associated phospholipase A2 activity promotes the development of vulnerable atherosclerotic plaques, and elevated plasma levels of this enzyme are associated with an increased risk of coronary events. Darapladib is a selective oral inhibitor of lipoprotein-associated phospholipase A2. METHODS: In a double-blind trial, we randomly assigned 15,828 patients with stable coronary heart disease to receive either once-daily darapladib (at a dose of 160 mg) or placebo. The primary end point was a composite of cardiovascular death, myocardial infarction, or stroke. Secondary end points included the components of the primary end point as well as major coronary events (death from coronary heart disease, myocardial infarction, or urgent coronary revascularization for myocardial ischemia) and total coronary events (death from coronary heart disease, myocardial infarction, hospitalization for unstable angina, or any coronary revascularization). RESULTS: During a median follow-up period of 3.7 years, the primary end point occurred in 769 of 7924 patients (9.7%) in the darapladib group and 819 of 7904 patients (10.4%) in the placebo group (hazard ratio in the darapladib group, 0.94; 95% confidence interval [CI], 0.85 to 1.03; P=0.20). There were also no significant between-group differences in the rates of the individual components of the primary end point or in all-cause mortality. Darapladib, as compared with placebo, reduced the rate of major coronary events (9.3% vs. 10.3%; hazard ratio, 0.90; 95% CI, 0.82 to 1.00; P=0.045) and total coronary events (14.6% vs. 16.1%; hazard ratio, 0.91; 95% CI, 0.84 to 0.98; P=0.02). CONCLUSIONS: In patients with stable coronary heart disease, darapladib did not significantly reduce the risk of the primary composite end point of cardiovascular death, myocardial infarction, or stroke. (Funded by GlaxoSmithKline; STABILITY ClinicalTrials.gov number, NCT00799903.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Furthermore, no change in Lp-PLA2 over time was observed in the placebo arms of trials evaluating potential inhibitors of this pathway 18,19 or in studies of stability of circulating Lp-PLA2 levels over time.20”
From Effects of Randomized Treatment With Icosapent Ethyl and a Mineral Oil Comparator on Interleukin-1β, Interleukin-6, C-Reactive Protein, Oxidized Low-Density Lipoprotein Cholesterol, Homocysteine, Lipoprotein(a), and Lipoprotein-Associated Phospholipase A2: A REDUCE-IT Biomarker Substudy (2022) · cites this paper as [18]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bhatt, D. L. (2006) · JAMA · doi:10.1001/jama.295.2.180 · Cited by 1,644
Concept of Vulnerable/Unstable Plaque
Finn, A. V., Nakano, M., Narula, J., Kolodgie, F. D., & Virmani, R. (2010) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.108.179739 · Cited by 1,193
Bhatt, D. L., Eagle, K. A., Ohman, E. M., Hirsch, A. T., Goto, S., Mahoney, E. M., Wilson, P. W. F., Alberts, M. J., D’Agostino, R., Liau, C.-S., et al. (2010) · JAMA · doi:10.1001/jama.2010.1322 · Cited by 753
Steg, P. G., Greenlaw, N., Tardif, J., Tendera, M., Ford, I., Kääb, S., Abergel, H., Fox, K. M., Ferrari, R., & on behalf of the CLARIFY Registry Investigators (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs289 · Cited by 653
Serruys, P. W. J. C., García‐García, H. M., Buszman, P. E., Erné, P., Verheye, S., Aschermann, M., Duckers, H., Bleie, Ø., Dudek, D., Bøtker, H. E., et al. (2008) · Circulation · doi:10.1161/circulationaha.108.771899 · Cited by 498
Wilensky, R. L., Shi, Y., Mohler, E. R., Hamamdzic, D., Burgert, M. E., Li, J., Postle, A. D., Fenning, R. S., Bollinger, J. G., Hoffman, B. E., et al. (2008) · Nature Medicine · doi:10.1038/nm.1870 · Cited by 389
Macphee, C. H., Moores, K., Boyd, H., Dhanak, D., Ife, R. J., Leach, C. A., Leake, D. S., Milliner, K. J., Patterson, R. A., Suckling, K. E., et al. (1999) · Biochemical Journal · doi:10.1042/bj3380479 · Cited by 359
Detection of Chronic Kidney Disease in Patients With or at Increased Risk of Cardiovascular Disease
Brosius, F. C., Hostetter, T. H., Kelepouris, E., Mitsnefes, M. M., Moe, S. M., Moore, M. A., Pennathur, S., Smith, G. L., & Wilson, P. W. F. (2006) · Circulation · doi:10.1161/circulationaha.106.177321 · Cited by 325
Kolodgie, F. D., BURKE, A. P., Skorija, K., Ladich, E. R., Kutys, R., Makuria, A. T., & Virmani, R. (2006) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000244681.72738.bc · Cited by 307
Häkkinen, T., Luoma, J. S., Hiltunen, M., Macphee, C. H., Milliner, K. J., Patel, L., Rice, S. Q. J., Tew, D. G., Karkola, K. O., & Ylä‐Herttuala, S. (1999) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.19.12.2909 · Cited by 239
O’Donoghue, M. L., Morrow, D. A., Sabatine, M. S., Murphy, S. A., McCabe, C. H., Cannon, C. P., & Braunwald, E. (2006) · Circulation · doi:10.1161/circulationaha.105.612630 · Cited by 228
Takahashi, M., Okazaki, H., Ogata, Y., Takeuchi, K., Ikeda, U., & Shimada, K. (2002) · Atherosclerosis · doi:10.1016/s0021-9150(01)00674-8 · Cited by 150
Role of lipoprotein-associated phospholipase A2 in leukocyte activation and inflammatory responses
Shi, Y., Zhang, P., Zhang, L., Osman, H. E., Mohler, E. R., Macphee, C. H., Zalewski, A. A., Postle, A. D., & Wilensky, R. L. (2006) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2006.05.001 · Cited by 136
Blackie, J. A., Bloomer, J. C., Brown, M. J. B., Cheng, H., Hammond, B., Hickey, D. M. B., Ife, R. J., Leach, C. A., Lewis, V. A., Macphee, C. H., et al. (2003) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(03)00058-1 · Cited by 128
White, H. D., Held, C., Stewart, R., Watson, D. I., Harrington, R. A., Budaj, A., Steg, P. G., Cannon, C. P., Krug‐Gourley, S., Wittes, J. T., et al. (2010) · American Heart Journal · doi:10.1016/j.ahj.2010.07.006 · Cited by 124
Carpenter, K. L. H., Dennis, I. F., Challis, I. R., Osborn, D. P., Macphee, C. H., Leake, D. S., Arends, M. J., & Mitchinson, M. J. (2001) · FEBS Letters · doi:10.1016/s0014-5793(01)02840-x · Cited by 114
Hsieh, C.-C., Yen, M., Liu, H.-W., & Lau, Y. (2000) · Atherosclerosis · doi:10.1016/s0021-9150(00)00453-6 · Cited by 100
Ridker, P. M., MacFadyen, J. G., Wolfert, R. L., & Köenig, W. (2012) · Clinical Chemistry · doi:10.1373/clinchem.2011.180281 · Cited by 79
White, H. D., Simes, J. R., Stewart, R., Blankenberg, S., Barnes, E. H., Marschner, I. C., Thompson, P. L., West, M., Zeller, T., Colquhoun, D. M., et al. (2013) · Journal of the American Heart Association · doi:10.1161/jaha.113.000360 · Cited by 66
Self-citationHeart Protection Study Collaborative Group (2010) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2010.02258.x · Cited by 42
Johnson, J. L., Shi, Y., Snipes, R., Janmohamed, S. G., Rolfe, T., Davis, B., Postle, A. D., & Macphee, C. H. (2014) · PLoS ONE · doi:10.1371/journal.pone.0089034 · Cited by 26
Flagged first, then by citations
Research works printed but not linked: 1
- 10.1042/0264-6021:3380479 · DOI
Cited by
Sorted by citations
Drug repurposing: progress, challenges and recommendations
Pushpakom, S., Iorio, F., Eyers, P. A., Escott, K. J., Hopper, S., Wells, A., Doig, A., Guilliams, T., Latimer, J., McNamee, C., et al. (2019) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.168 · Cited by 4,718
Colchicine in Patients with Chronic Coronary Disease
Nidorf, S. M., Fiolet, A. T. L., Mosterd, A., Eikelboom, J. W., Schut, A., Opstal, T. S. J., The, S. H. K., Xu, X.-F., Ireland, M. A., Lenderink, T., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2021372 · Cited by 2,299
The immunology of atherosclerosis
Gisterå, A., & Hansson, G. K. (2017) · Nature Reviews Nephrology · doi:10.1038/nrneph.2017.51 · Cited by 982
Mendelian randomization in cardiometabolic disease: challenges in evaluating causality
Holmes, M. V., Ala-Korpela, M., & Smith, G. D. (2017) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2017.78 · Cited by 679
Genetics of coronary artery disease: discovery, biology and clinical translation
Khera, A. V., & Kathiresan, S. (2017) · Nature Reviews Genetics · doi:10.1038/nrg.2016.160 · Cited by 659
Metadata
- Authors
- The STABILITY Investigators
- Affiliations
- University of Auckland (NZ)
- Corresponding author
- The STABILITY Investigators
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-05
- Volume
- 370
- Issue
- 18
- Pages
- 1702-1711
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1572528121
- Cited by
- 579
- References
- 22
- Citations by year
- 2026: 23 · 2025: 34 · 2024: 33 · 2023: 27 · 2022: 47 · 2021: 38 · 2020: 34 · 2019: 36 · 2018: 48 · 2017: 63 · 2016: 71 · 2015: 85 · 2014: 37
- FWCI
- 85.88
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- RECERCAT (Consorci de Serveis Universitaris de Catalunya) (publishedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- KTH Publication Database DiVA (KTH Royal Institute of Technology) (submittedVersion, other-oa)
- Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona) (submittedVersion, public-domain)
- The HKU Scholars Hub (University of Hong Kong) (submittedVersion)
- Pure Amsterdam UMC (submittedVersion)
- Spiral (Imperial College London) (submittedVersion)
- UEA Digital Repository (University of East Anglia) (submittedVersion)
- Funders
- Uppsala Universitet
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Immunology and Microbiology › Immunology › Atherosclerosis and Cardiovascular Diseases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Paraoxonase enzyme and polymorphisms
- Keywords
- darapladib, lipoprotein-associated phospholipase A2, stable coronary artery disease, cardiovascular events, myocardial infarction, stroke, cardiovascular mortality, major coronary events, all-cause mortality, atherosclerotic plaque vulnerability, lipid-lowering therapy, unstable angina
- MeSH terms
- Aged, Benzaldehydes, Biphenyl Compounds, Coronary Artery Disease, Coronary Disease, Diethylamines, Double-Blind Method, Female, Follow-Up Studies, Humans, Male, Middle Aged, Myocardial Infarction, Oximes, Pyrimidinones, Sulfides, Treatment Failure, Stroke, Kaplan-Meier Estimate, Phospholipase A2 Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
